Gland Pharma Q2 Review - Robust Show Despite Industry Headwinds: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report.Gland Pharma Ltd. delivered in-line Q2 FY22 results, led by a strong revenue growth across all geographies, despite increasing cost pressure on account of supply disruptions. With vaccine batch validation completed for Sputnik Lite and second dose, the company awaits clarity on the lifting of export restrictions by the government. We lower our earnings per share estimate by 4%/2% for FY22/FY23, mainly to factor in some delay in commercialisation of the Sputnik contract. We remain positive on Gland Pharma based on its-complex product filings including peptides, long-acting injectables for regulated markets, commercialisation of the Sputnik vaccine manufacturing contract,rapid expansion in rest of world markets, and better operating leverage across markets..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Gland Pharma Q2 Review - Robust Show Despite Industry Headwinds: Motilal Oswal

Gland Pharma Q2 Review - Robust Show Despite Industry Headwinds: Motilal Oswal

Choose a plan